Company raises $ 56 million to fight rare diseases using artificial intelligence
https://newsstechh.blogspot.com/2019/10/company-raises-56-million-to-fight-rare.html
Company raises $ 56 million to fight rare diseases using artificial intelligence
Healx, a company that uses artificial intelligence (AI) to discover new drug treatments for rare diseases, raised $ 56 million in the B series of financing led by international investment company Atomico, with the participation of Intel Capital, Balderton Capital, Global Brain, Btov Partners and Amadeus Capital. And Jonathan Milner of Cambridge Innovation University
Founded outside of Cambridge in 2014, Healx owns the Healnet platform for artificial intelligence that applies a range of machine learning techniques to public and proprietary data sources, covering literature, clinical trials, patents, drug targets, chemical structures, symptoms, and more. Part of this process involves the use of Natural Language Processing (NLP) to extract insights and knowledge from all published sources about specific diseases.
Healx's CEO and founder, Dr. Tim Guilliams, said:
“We use a variety of machine learning algorithms to solve many of the tasks needed to effectively predict and translate drug treatments in the clinic,” Guilliams told VentureBeat: “We use deep artificial intelligence algorithms that predict new relationships between drugs and disease, for example. As the "complete knowledge base" is based on a comprehensive cognitive graph of rare disease data. "
Healx, a company that uses artificial intelligence (AI) to discover new drug treatments for rare diseases, raised $ 56 million in the B series of financing led by international investment company Atomico, with the participation of Intel Capital, Balderton Capital, Global Brain, Btov Partners and Amadeus Capital. And Jonathan Milner of Cambridge Innovation University
Founded outside of Cambridge in 2014, Healx owns the Healnet platform for artificial intelligence that applies a range of machine learning techniques to public and proprietary data sources, covering literature, clinical trials, patents, drug targets, chemical structures, symptoms, and more. Part of this process involves the use of Natural Language Processing (NLP) to extract insights and knowledge from all published sources about specific diseases.
Healx's CEO and founder, Dr. Tim Guilliams, said:
“We use a variety of machine learning algorithms to solve many of the tasks needed to effectively predict and translate drug treatments in the clinic,” Guilliams told VentureBeat: “We use deep artificial intelligence algorithms that predict new relationships between drugs and disease, for example. As the "complete knowledge base" is based on a comprehensive cognitive graph of rare disease data. "
